Company intelligence / Profile preview

Complement 1 Health

New York City, New York, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Complement 1’s platform has demonstrated clinical validation with users reporting a 37% reduction in treatment side effects, 18% less pain, and a 27% improvement in sleep. The program achieves over a 90% adherence rate among users. Early actuarial modeling suggests up to a 30% reduction in healthcare costs for cancer patients and high-risk individuals

Therapeutic areas: Oncology
Modalities: Non-pharmacological therapyDigital health interventionLifestyle modification programCoaching (CoActive Coaching)
Industry: Digital Health Medical Devices

Partnerships

Owl Ventures and Blume Ventures are lead investors.No major pharma/biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on Complement 1 Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement 1 Health.

Explore the full profile